penpulimab + gemcitabine + cisplatin + anlotinib

**Penpulimab + gemcitabine + cisplatin + anlotinib** is an experimental multi-drug combination used in oncology, typically investigated for treatment of advanced or metastatic solid tumors, including pancreatic cancer and nasopharyngeal carcinoma. - **Penpulimab** is a humanized IgG1 anti–PD-1 monoclonal antibody immune checkpoint inhibitor that blocks PD-1 and enhances T-cell–mediated antitumor activity. - **Gemcitabine** is a nucleoside analog (antimetabolite) chemotherapeutic that interferes with DNA synthesis, leading to cell death. - **Cisplatin** is a platinum-based chemotherapeutic that forms DNA crosslinks and induces apoptosis in rapidly dividing cells. - **Anlotinib** is a small molecule multi-target tyrosine kinase inhibitor (TKI) that inhibits angiogenesis and tumor proliferation (targets include VEGFR, FGFR, PDGFR, c-Kit). This combination aims to synergistically enhance anti-tumor efficacy through immune checkpoint inhibition, cytotoxic chemotherapy, and anti-angiogenic therapy. Indications under investigation include metastatic pancreatic cancer, upper gastrointestinal cancers, non-keratinizing nasopharyngeal carcinoma, and others[2][3][4][6].